TNYATenaya Therapeutics Inc. Common Stock

0.6973USD-2.19%Mkt Cap: 156.36M $P/E:

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin…

Key Statistics

Company
Market Cap156.36M $
Enterprise Value80.69M $
Revenue (TTM)1.33M $
Gross Profit1.33M $
Net Income (TTM)-90.60M $
Revenue/Share0.0070 USD
Last Price0.6973 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees70
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)
P/E (Forward)-1.76
PEG
EV/EBITDA-1.07
EV/Revenue60.45
P/S115.98
P/B1.41
EPS (TTM)-0.49
EPS (Forward)-0.39
52W Range
0.53209% of range2.350
52W High2.350 USD
52W Low0.5320 USD
Profitability
Gross Margin100.00%
Oper. Margin-1882.79%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-73.50%
ROA-61.66%
Growth
Revenue Growth
Earnings Growth
Cash Flow & Leverage
Operating CF-68.26M $
CapEx (TTM)618.00K $
FCF Margin-2441.99%
FCF Yield-20.85%
Net Debt-74.14M $
Net Debt/EBITDA0.98
Balance Sheet
Debt/Equity0.09
Current Ratio4.52
Quick Ratio4.13
Book Value/Sh0.4890 USD
Cash/Share0.3480 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.200 USD
Upside (mean)+358.9%
Target Range2.000 USD5.000 USD
$2.000+358.9% to mean$5.000
# Analysts5
Ownership
Shares Out.224.23M
Float223.32M
Insiders0.44%
Institutions46.55%
Short Interest
Short Ratio9.3d
Short % Float12.63%
Short % Out.9.81%
Shares Short21.99M
Short (prev mo.)26.23M
Technical
SMA 500.7621 (-8.5%)
SMA 2000.8356 (-16.6%)
Beta2.79
S&P 52W Chg18.16%
Avg Vol (30d)2.03M
Avg Vol (10d)2.14M
Technical Indicators
RSI (14)39.6
MACD-0.0188
MACD Signal-0.0143
MACD Hist.-0.0045
BB Upper0.7898 USD
BB Middle0.7415 USD
BB Lower0.6933 USD
BB Width13.01%
ATR (14)0.0447 USD
Vol Ratio (20d)0.55x